VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
MLAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
MLABMesa Laboratories, Inc.
$133.01$744M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. MLAB
  4. Financial Ratios

Mesa Laboratories, Inc. (MLAB) Financial Ratios

Latest Ratios: P/E Ratio 109.9x · EV/EBITDA 21.2x · ROE 3.9%. (1997–2026 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

MLAB Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$744M$492M$644M$591M$937M$1.4B$1.2B$988M$930M$560M$472M
Enterprise Value$886M$634M$798M$794M$1.1B$1.5B$1.1B$1.0B$942M$600M$521M
P/E Ratio →109.9373.07——1027.82728.23380.47729.32123.92—42.16
P/S Ratio2.991.982.672.734.287.389.328.409.015.825.04
P/B Ratio3.972.644.034.062.383.453.074.498.355.634.82
P/FCF18.8012.4315.2314.2239.9639.0835.5739.4331.7425.42—
P/OCF17.3811.4913.7613.3933.4734.6733.6637.2130.4322.5560.86

P/E links to full P/E history page with 30-year chart

MLAB EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue—2.543.313.674.988.318.448.919.146.245.56
EV / EBITDA21.2115.1719.54—29.9051.4537.6650.1248.9451.5220.78
EV / EBIT47.8752.7744.80—248.79205.33109.47111.92109.26278.7431.92
EV / FCF—16.0218.8719.1046.5044.0232.2341.8332.1627.27—

MLAB Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin63.5%63.5%62.6%61.6%61.0%59.2%65.0%55.5%59.1%56.8%56.8%
Operating Margin7.4%7.4%6.8%-125.9%1.5%2.6%9.2%6.7%9.5%2.3%17.4%
Net Profit Margin2.7%2.7%-0.8%-117.6%0.4%1.0%2.4%1.5%7.3%-3.1%11.9%

Return on Capital

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE3.9%3.9%-1.3%-94.4%0.2%0.5%1.0%1.1%7.1%-3.0%12.3%
ROA1.6%1.6%-0.4%-45.9%0.1%0.3%0.6%0.6%4.7%-1.8%6.7%
ROIC4.3%4.3%3.7%-45.6%0.4%0.8%3.3%2.9%5.6%1.1%9.0%
ROCE5.8%5.8%4.9%-53.3%0.5%0.8%2.6%3.0%7.0%1.4%11.2%

MLAB Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity0.910.911.141.590.470.560.360.640.200.470.56
Debt / EBITDA4.044.044.44—5.117.434.896.761.183.972.19
Net Debt / Equity—0.760.961.400.390.44-0.290.270.110.410.50
Net Debt / EBITDA3.403.403.77—4.205.77-3.902.870.653.501.96
Debt / FCF—3.593.644.896.544.94-3.342.390.431.85—
Interest Coverage1.121.121.50-47.380.921.921.291.70—1.16—

MLAB Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio1.721.720.632.472.742.599.324.721.421.852.16
Quick Ratio1.291.290.471.731.942.078.984.171.131.321.32
Cash Ratio0.440.440.170.640.761.038.103.130.430.320.35
Asset Turnover—0.580.560.480.330.260.220.280.660.590.55
Inventory Turnover3.453.453.552.542.463.064.203.686.234.502.91
Days Sales Outstanding—64.6163.5765.9470.8981.6364.8265.5444.2954.2855.80

MLAB Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield0.5%0.7%0.5%0.6%0.4%0.2%0.3%0.3%0.3%0.4%0.5%
Payout Ratio52.5%52.5%——366.2%178.5%96.7%153.1%32.9%—21.1%

Total Shareholder Return Metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield0.9%1.4%——0.1%0.1%0.3%0.1%0.8%—2.4%
FCF Yield5.3%8.0%6.6%7.0%2.5%2.6%2.8%2.5%3.2%3.9%—
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.5%0.0%0.0%
Total Shareholder Yield0.5%0.7%0.5%0.6%0.4%0.2%0.3%0.3%0.8%0.4%0.5%
Shares Outstanding—$6M$5M$5M$5M$5M$5M$4M$4M$4M$4M

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Erratic Profitability and Growth

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2027Q1)

Pricing in a Strong Recovery Narrative

The forward P/E of 14.19 suggests the market is pricing in a significant earnings recovery, a stark contrast to the trailing P/E of 106.32 which is heavily distorted by volatile and non-recurring items in recent periods.

This valuation disconnect indicates investors are looking past the erratic historical earnings and projecting a normalized profitability level well above recent results. The 7.83 PEG ratio further confirms that current market pricing embeds expectations of future earnings acceleration, which appears highly contingent on the company's ability to stabilize its gross margins and execute on operational improvements.

Gross Margin Volatility Masks Core Earnings

Gross margin has swung by over 1,800 basis points in a single year, from 54.6% in Q1 2026 to 73.2% in Q4 2026, making it an unreliable indicator of underlying operational performance.

The extreme volatility in gross margin, paired with inconsistent operating margins ranging from 2.4% to 12.2%, suggests the business is subject to significant one-time impacts, pricing variability, or unstable cost of goods sold. Consequently, core profitability appears more accurately reflected by the recent stabilization of operating margin in the mid-single to low-double digits, but this still represents a modest return given the company's cost structure.

Compounding Value Destruction vs. Cash Flow

ROIC has been below 2% for nine of the last ten quarters, a stark contrast to the robust free cash flow margins, suggesting a severe disconnect between cash generation and long-term value creation for shareholders.

This persistent low return on invested capital, especially when viewed alongside the massive retained earnings deficit of -$183.8M reported in the latest balance sheet, indicates a history of capital allocation that has destroyed book value. The recent improvement in ROIC to 1.8% in Q1 2027 is encouraging but remains deeply below the cost of capital, implying the business is not yet creating economic value.

Lengthy Cash Cycle Highlights Working Capital Drag

The cash conversion cycle has consistently exceeded 130 days over the past ten quarters, primarily due to high days inventory outstanding averaging 119 days, which ties up significant capital and suppresses cash flow efficiency.

This prolonged cycle, with DSO also elevated around 60 days, suggests the company may face challenges in inventory management or holds specialized, slow-moving stock. While the cycle has recently compressed to 148 days from a high of 176 days, it remains a substantial operational drag on the return of cash to the business.

Deleveraging Improves Interest Coverage

The company's aggressive debt repayment has slashed the D/E ratio from 1.55 to 0.54, causing interest coverage to swing from a negative -144.83 in Q4 2024 to a comfortable 2.84 in Q1 2027.

This rapid improvement in the leverage profile reduces refinancing risk and should lower financial volatility going forward. However, the interest coverage metric has been erratic, swinging from negative to positive territory multiple times, which underscores that the balance sheet's stability is now more dependent on consistent operating profitability than on the debt structure itself.

The Misleading Stability of Current Ratio

The current ratio of 2.07 appears strong but is dangerously misleading because 44% of total assets are comprised of goodwill, a non-liquid asset that provides no real short-term cash coverage.

Investors relying on this headline liquidity metric are obscuring the underlying weakness of the asset base. A more accurate stress-test would exclude goodwill and intangibles entirely, which would dramatically reduce the ratio and reveal a much tighter, potentially vulnerable, liquidity position. The ratio's sharp deterioration to below 1.0 in late 2025 further demonstrates its historical instability and the company's past reliance on operational cash flow to meet obligations.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open MLAB Terminal

MLAB Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MLAB — Frequently Asked Questions

Quick answers to the most common questions about buying MLAB stock.

What is Mesa Laboratories, Inc.'s P/E ratio?

Mesa Laboratories, Inc.'s current P/E ratio is 109.9x. The historical average is 25.1x. This places it at the 96th percentile of its historical range.

What is Mesa Laboratories, Inc.'s EV/EBITDA?

Mesa Laboratories, Inc.'s current EV/EBITDA is 21.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.5x.

What is Mesa Laboratories, Inc.'s ROE?

Mesa Laboratories, Inc.'s return on equity (ROE) is 3.9%. The historical average is 9.0%.

Is MLAB stock overvalued?

Based on historical data, Mesa Laboratories, Inc. is trading at a P/E of 109.9x. This is at the 96th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is Mesa Laboratories, Inc.'s dividend yield?

Mesa Laboratories, Inc.'s current dividend yield is 0.48% with a payout ratio of 52.5%.

What are Mesa Laboratories, Inc.'s profit margins?

Mesa Laboratories, Inc. has 63.5% gross margin and 7.4% operating margin.

How much debt does Mesa Laboratories, Inc. have?

Mesa Laboratories, Inc.'s Debt/EBITDA ratio is 4.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.